Nuo Highlights Strong Q3 Revenues, Expands Medicare Reimbursement Scope
Nuo Therapeutics reported a 123% increase in revenues for the first nine months of 2026 driven by its Aurix wound care product line. The company announced expanded coverage for its G0465 treatment code within nursing home settings effective January 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed